

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Three Months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands

<u>Assets</u>	<u>March 31, 2015</u>		<u>December 31, 2014</u>		<u>March 31, 2014</u>		
	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>	
<b>Current Assets</b>							
1100	Cash and Cash Equivalents	\$ 682,285	7	\$ 795,907	8	\$ 783,401	7
1150	Notes Receivable	373,746	4	341,765	3	349,876	3
1160	Notes Receivable - Related Parties	185,975	2	160,072	2	217,236	2
1170	Accounts Receivable	1,020,414	10	978,370	9	922,889	8
1180	Accounts Receivable - Related Parties	55,904	-	85,694	1	97,796	1
1200	Other Receivables	58,883	1	42,960	-	61,823	1
1210	Other Receivables -Related Parties	157,625	1	161,277	2	160,994	1
1220	Current Income Tax Assets	-	-	1,016	-	-	-
130X	Inventories	1,541,182	15	1,547,744	15	1,427,252	13
1410	Prepayments	88,239	1	62,012	1	65,726	1
1460	Non-current classified as held for sale	202,746	2	202,746	2	-	-
1476	Other Financial Assets- Current	9,274	-	17,722	-	28,947	-
11XX	<b>Total Current Assets</b>	<u>4,376,273</u>	<u>43</u>	<u>4,397,285</u>	<u>43</u>	<u>4,115,940</u>	<u>37</u>
<b>Non-Current assets</b>							
1523	Available-for-sale Financial Assets- Noncurrent	337,190	3	435,782	4	331,482	3
1543	Financial Assets at Cost - Noncurrent	15,710	-	15,710	-	710	-
1550	Long-term Investments at Equity	754,110	8	701,450	7	707,715	6
1600	Property, Plant and Equipment	4,304,062	42	4,297,122	42	5,100,244	46
1760	Investment Property	-	-	27,856	-	232,174	2
1780	Intangible Assets	9,477	-	9,900	-	10,587	-
1840	Deferred Tax Assets	174,109	2	170,585	2	156,433	2
1900	Other Non-current Assets	223,880	2	254,171	2	473,527	4
15XX	<b>Total Non-Current Assets</b>	<u>5,818,538</u>	<u>57</u>	<u>5,912,576</u>	<u>57</u>	<u>7,012,872</u>	<u>63</u>
1XXX	<b>Total Assets</b>	<u>\$ 10,194,811</u>	<u>100</u>	<u>\$ 10,309,861</u>	<u>100</u>	<u>\$ 11,128,812</u>	<u>100</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Three Months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands

	March 31, 2015		December 31, 2014		March 31, 2014		
	Amount	%	Amount	%	Amount	%	
<b>Liabilities and Shareholders' Equity</b>							
<b>Current Liabilities</b>							
2100	Short-term Borrowings	\$ 1,162,226	11	\$ 1,269,899	12	\$ 1,306,048	12
2110	Short-Term Notes and Bills Payable	122,978	1	222,978	2	320,000	3
2150	Notes Payable	46,741	-	88,610	1	144,730	1
2170	Accounts Payable	568,434	6	538,031	5	546,904	5
2200	Other Payables	296,046	3	358,314	4	296,553	3
2230	Current Income Tax Liabilities	64,703	1	47,328	1	28,913	-
2250	Short-term Provisions	98,980	1	98,980	1	98,980	1
2300	Other Current Liabilities	54,229	1	36,054	-	24,405	-
21XX	<b>Total Non-Current Liabilities</b>	<u>2,414,337</u>	<u>24</u>	<u>2,660,194</u>	<u>26</u>	<u>2,766,533</u>	<u>25</u>
<b>Non-Current Liabilities</b>							
2540	Long-term Borrowings	1,745,000	17	1,625,000	16	1,675,000	15
2570	Deferred Income Tax Liabilities	130,354	1	131,245	1	120,330	1
2600	Other Non-Current Liabilities	404,760	4	409,870	4	1,420,712	13
25XX	<b>Total Non-Current Liabilities</b>	<u>2,280,114</u>	<u>22</u>	<u>2,166,115</u>	<u>21</u>	<u>3,216,042</u>	<u>29</u>
2XXX	<b>Total Liabilities</b>	<u>4,694,451</u>	<u>46</u>	<u>4,826,309</u>	<u>47</u>	<u>5,982,575</u>	<u>54</u>
<b>Equity Attributable to Owners of Parent</b>							
<b>Share Capital</b>							
3110	Ordinary Share	2,980,811	29	2,980,811	29	2,980,811	27
<b>Capital Surplus</b>							
3200	Capital Surplus	642,284	7	642,284	6	641,987	5
<b>Retained Earnings</b>							
3310	Legal Reserve	327,457	3	327,457	3	303,422	3
3320	Special Reserve	188,958	2	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	1,147,976	11	1,042,487	10	939,516	8
<b>Other Equity Interest</b>							
3400	Other Interest	194,345	2	303,594	3	94,884	1
3500	Treasury Stock	( 28,054)	-	( 28,054)	-	( 28,054)	-
31XX	<b>Total Equity Attributable to Shareholders of the Parent</b>	<u>5,453,777</u>	<u>54</u>	<u>5,457,537</u>	<u>53</u>	<u>5,121,524</u>	<u>46</u>
36XX	<b>Noncontrolling Interests</b>	<u>46,583</u>	<u>-</u>	<u>26,015</u>	<u>-</u>	<u>24,713</u>	<u>-</u>
3XXX	<b>Total Shareholders' Equity</b>	<u>5,500,360</u>	<u>54</u>	<u>5,483,552</u>	<u>53</u>	<u>5,146,237</u>	<u>46</u>
Significant Contingent Liability&Unrealized Contractual Arrangement							
3X2X	<b>Total Liabilities &amp; Shareholders' Equity</b>	<u>\$ 10,194,811</u>	<u>100</u>	<u>\$ 10,309,861</u>	<u>100</u>	<u>\$ 11,128,812</u>	<u>100</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Comprehensive Income (Reviewed, Not Audited)**  
**Three months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands  
(EPS: NT Dollars)

Item	M a r c h 3 1 , 2 0 1 5		M a r c h 3 1 , 2 0 1 4	
	Amount	%	Amount	%
4000 Operating Revenue	\$ 1,414,903	100	\$ 1,362,421	100
5000 Operating Costs	( 981,692)	( 69)	( 942,089)	( 69)
5950 <b>Gross Profit from Operations</b>	<u>433,211</u>	<u>31</u>	<u>420,332</u>	<u>31</u>
<b>Operating Expenses</b>				
6100 Selling Expenses	( 223,115)	( 16)	( 207,219)	( 15)
6200 Administrative Expenses	( 50,004)	( 4)	( 39,273)	( 3)
6300 Research and Development Expenses	( 88,052)	( 6)	( 92,584)	( 7)
6000 <b>Total Operating Expenses</b>	<u>( 361,171)</u>	<u>( 26)</u>	<u>( 339,076)</u>	<u>( 25)</u>
6900 <b>Net Operating Income</b>	<u>72,040</u>	<u>5</u>	<u>81,256</u>	<u>6</u>
<b>Non- Operating Income and Expenses</b>				
7010 Other Revenue	8,843	1	10,974	1
7020 Other Gains and Losses	( 1,498)	-	( 5,326)	( 1)
7050 Finance Cost	( 9,639)	( 1)	( 11,243)	( 1)
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)	<u>52,704</u>	<u>4</u>	<u>12,896</u>	<u>1</u>
7000 <b>Total Non-Operating Income and Expenses</b>	<u>50,410</u>	<u>4</u>	<u>7,301</u>	<u>-</u>
7900 <b>Income Before Income Tax</b>	<u>122,450</u>	<u>9</u>	<u>88,557</u>	<u>6</u>
7950 Income Tax Expense	( 16,393)	( 1)	( 19,279)	( 1)
8200 <b>Net Income</b>	<u>\$ 106,057</u>	<u>8</u>	<u>\$ 69,278</u>	<u>5</u>
<b>Other Comprehensive Income that will be Reclassified to Profit or Loss</b>				
8361 Exchange Differences on Translation of Foreign Financial Statements	(\$ 12,787)	( 1)	\$ 2,585	-
8362 Unrealised Gains (Losses) on Valuation of Available-for-sale Financial Assets	( 98,592)	( 7)	( 14,146)	( 1)
8370 Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Accounted for Using Equity Method - Will be Reclassified to Profit	( 44)	-	345	-
8399 Income Tax Relating to Components of Other Comprehensive Income	<u>2,174</u>	<u>-</u>	<u>( 440)</u>	<u>-</u>
8300 <b>Total Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss After Tax</b>	<u>(\$ 109,249)</u>	<u>( 8)</u>	<u>(\$ 11,656)</u>	<u>( 1)</u>
8500 <b>Total Other Comprehensive Income and Loss</b>	<u>(\$ 3,192)</u>	<u>-</u>	<u>\$ 57,622</u>	<u>4</u>
<b>Net Income (Losses) Attributable to:</b>				
8610 Shareholders of the Parent	<u>\$ 105,489</u>	<u>8</u>	<u>\$ 68,835</u>	<u>5</u>
8620 Non-controlling Interests	<u>\$ 568</u>	<u>-</u>	<u>\$ 443</u>	<u>-</u>
<b>Comprehensive Income Attributable to:</b>				
8710 Shareholders of the Parent	<u>(\$ 3,760)</u>	<u>-</u>	<u>\$ 57,287</u>	<u>4</u>
8720 Non-controlling Interests	<u>\$ 568</u>	<u>-</u>	<u>\$ 335</u>	<u>-</u>
<b>Earnings per Share</b>				
9750 <b>Diluted Earnings Per Share</b>	<u>\$</u>	<u>0.35</u>	<u>\$</u>	<u>0.23</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statement of Changes in Equity (Reviewed, Not Audited)**  
**Three months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands

	Total Capital		Equity Surplus		Attributable to Retained Earnings		Owners Other	Equity		Parent		
	Ordinary Share	Additional Paid-In Capital	Treasury Stock Transactions	Legal Reserve	Special Reserve	Unappropriated Retained Earnings	Exchange Differences on Translation	Unrealized Gains(Losses) on Available-for-sale Financial Assets	Treasury Stock	Total	Non-controlling Interests	Total Equity
<b>January 1st to March 31, 2014</b>												
Equity at Beginning Of Period	\$2,980,811	\$ 578,416	\$ 63,571	\$ 303,422	\$ 188,958	\$ 870,681	\$ 19,597	\$ 86,835	(\$ 28,054 )	\$5,064,237	\$ 24,378	\$5,088,615
Consolidated Profit for The Year Ended March 31, 2014	-	-	-	-	-	68,835	-	-	-	68,835	443	69,278
Other Comprehensive Income	-	-	-	-	-	-	2,321	( 13,869 )	-	( 11,548 )	( 108 )	( 11,656 )
Balance, March 31, 2014	<u>\$2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 63,571</u>	<u>\$ 303,422</u>	<u>\$ 188,958</u>	<u>\$ 939,516</u>	<u>\$ 21,918</u>	<u>\$ 72,966</u>	<u>(\$ 28,054 )</u>	<u>\$5,121,524</u>	<u>\$ 24,713</u>	<u>\$5,146,237</u>
<b>January 1st to March 31, 2015</b>												
Equity at Beginning Of Period	\$2,980,811	\$ 578,416	\$ 63,868	\$ 327,457	\$ 188,958	\$1,042,481	\$ 63,345	\$ 240,249	(\$ 28,054 )	\$5,457,537	\$ 26,015	\$5,483,552
Consolidated Profit for The Year Ended March 31, 2015	-	-	-	-	-	105,489	-	-	-	105,489	568	106,057
Other Comprehensive Income	-	-	-	-	-	-	( 10,657 )	( 98,592 )	-	( 109,249 )	-	( 109,249 )
Changes in Non-controlling interests	-	-	-	-	-	-	-	-	-	-	20,000	20,000
Balance, March 31, 2015	<u>\$2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 63,868</u>	<u>\$ 327,457</u>	<u>\$ 188,958</u>	<u>\$1,147,970</u>	<u>\$ 52,688</u>	<u>\$ 141,657</u>	<u>(\$ 28,054 )</u>	<u>\$5,453,777</u>	<u>\$ 46,583</u>	<u>\$5,500,360</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Three months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands

**For the Three Months Ended March 31**  
March 31, 2015                      March 31, 2015

**Cash Flows From (Used in) Operating Activities**

Consolidated Profit (Loss) Before Tax	\$	122,450	\$	88,557
Adjustments				
Depreciation expense		59,824		48,871
Amortized Expense		423		171
Bad Debts Recognized Revenue	(	1,569	)	2,598
Decrease in Allowance for Sales Returns and Allowances		1,396	(	8,834
Interest Expense		9,639		11,243
Interest Revenue	(	3,140	)	( 1,630
Share of gain (loss) of Associates and Joint Ventures Accounted for Using Equity Method	(	52,704	)	( 12,896
Gain on Disposal of Investments		-	(	743
Gain on Disposal of Property, Plant and Equipment		-	(	1,193
Notes Receivable (Include Related Parties)	(	56,305	)	3,696
Accounts Receivable (Include Related Parties)	(	16,155	)	( 8,437
Other Receivable (Include Related Parties)	(	14,668	)	( 20,879
Inventories		3,112		27,784
Prepayments	(	26,532	)	( 11,138
Notes Payable	(	41,000	)	30,749
Accounts Payable		32,920		21,030
Other Payable	(	34,353	)	( 46,506
Other Current Liabilities		18,358	(	8,561
Other Non-Current Liabilities	(	2,957	)	( 2,590
<b>Cash Inflow (Outflow) Generated from Operations</b>	(	1,261	)	111,292
Interest Received		3,162		3,010
Interest Paid	(	9,990	)	( 11,244
Income Taxes Refund (Paid)	(	1,858	)	( 6,562
<b>Net Cash Flows from (used in) Operating Activities</b>	(	9,947	)	96,496

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Three months Ended March 31, 2015 and 2014**

Unit : NT\$ Thousands

	<b>For the Three Months Ended March 31</b>	
	March 31, 2015	March 31, 2015
<b><u>Cash Flows From (Used in) Investing Activities</u></b>		
Decrease(Increase) in Financing Receivable	\$ 2,234	(\$ 51,749 )
Decrease(Increase) in Pledged Deposit	8,448	( 6,143 )
Disposal of Available-for-sale Financial Assets	-	4,096
Purchase of Property, Plant and Equipment	( 70,560 )	( 92,862 )
Disposal of Property, Plant and Equipment	10	5,514
Purchase of Investment Property	-	( 1,202 )
Decrease(Increase) in Refundable Deposits	534	5,677
Decrease(Increase) in Prepaid Investment	30,000	-
Decrease(Increase) in Other Non-current Assets	( 270 )	( 918 )
<b>Net Cash Flows From (Used in) Investing Activities</b>	<b>( 29,604 )</b>	<b>( 137,587 )</b>
<b><u>Cash flows from (used in) Financing Activities</u></b>		
Decrease(Increase) In Short-term Borrowings	( 206,527 )	( 325,725 )
Decrease(Increase) in Short-term Notes and Bills Payable	( 1,146 )	207,076
Proceeds from Long-term Borrowings	150,000	730,000
Repayment of Long-term Borrowings	( 30,000 )	( 610,000 )
Decrease(Increase) in Guarantee Deposits Received	( 1,936 )	2,388
Non-controlling Interests change	20,000	-
<b>Net cash FlowsFrom (Used in) Financing Activities</b>	<b>( 69,609 )</b>	<b>3,739</b>
Effect of Exchange Rate Changes on Cash and Cash Equivalents	( 4,462 )	2,098
Net Increase (Decrease) In Cash and Cash Equivalents	( 113,622 )	( 35,254 )
Cash and Cash Equivalents at Beginning of Period	795,907	818,655
Cash and Cash Equivalents at End of Period	\$ 682,285	\$ 783,401